These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8310507)

  • 1. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. I. Results after combined pancreas and kidney transplantation.
    Cantarovich D; Le Mauff B; Hourmant M; Dantal J; Baatard R; Denis M; Jacques Y; Karam G; Paineau J; Soulillou JP
    Transplantation; 1994 Jan; 57(2):198-203. PubMed ID: 8310507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. II. Results after a second kidney transplantation.
    Hourmant M; Le Mauff B; Cantarovich D; Dantal J; Baatard R; Denis M; Jacques Y; Karam G; Soulillou JP
    Transplantation; 1994 Jan; 57(2):204-7. PubMed ID: 8310508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.
    Soulillou JP; Cantarovich D; Le Mauff B; Giral M; Robillard N; Hourmant M; Hirn M; Jacques Y
    N Engl J Med; 1990 Apr; 322(17):1175-82. PubMed ID: 2157982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation.
    Cantarovich D; Karam G; Giral-Classe M; Hourmant M; Dantal J; Blancho G; Le Normand L; Soulillou JP
    Kidney Int; 1998 Oct; 54(4):1351-6. PubMed ID: 9767555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin 2.
    Soulillou JP; Peyronnet P; Le Mauff B; Hourmant M; Olive D; Mawas C; Delaage M; Hirn M; Jacques Y
    Lancet; 1987 Jun; 1(8546):1339-42. PubMed ID: 2884454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-interleukin 2 receptor monoclonal antibody in the treatment of ongoing acute rejection episodes of human kidney graft--a pilot study.
    Cantarovich D; Le Mauff B; Hourmant M; Giral M; Denis M; Hirn M; Jacques Y; Soulillou JP
    Transplantation; 1989 Mar; 47(3):454-7. PubMed ID: 2646778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation.
    Langrehr JM; Nüssler NC; Neumann U; Guckelberger O; Lohmann R; Radtke A; Jonas S; Klupp J; Steinmüller T; Lobeck H; Meuer S; Schlag H; Lemmens HP; Knoop M; Keck H; Bechstein WO; Neuhaus P
    Transplantation; 1997 Jun; 63(12):1772-81. PubMed ID: 9210503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
    Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
    Schulz T; Papapostolou G; Schenker P; Kapischke M
    Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic use of a monoclonal antibody (33B3.1) directed against interleukin 2 receptor following human renal transplantation.
    Cantarovich D; Le Mauff B; Hourmant M; Peyronnet P; Jacques Y; Boeffard F; Hirn M; Soulillou JP
    Am J Kidney Dis; 1988 Feb; 11(2):101-6. PubMed ID: 3124608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin.
    van de Linde P; Vd Boog PJ; Tysma OM; Elliott JF; Roelen DL; Claas FH; de Fijter JW; Roep BO
    Clin Exp Immunol; 2007 Jul; 149(1):56-62. PubMed ID: 17459076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients.
    Nashan B; Schlitt HJ; Schwinzer R; Ringe B; Kuse E; Tusch G; Wonigeit K; Pichlmayr R
    Transplantation; 1996 Feb; 61(4):546-54. PubMed ID: 8610379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
    Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
    J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
    N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
    Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
    Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction.
    Cantarovich D; Rostaing L; Kamar N; Saint-Hillier Y; Ducloux D; Mourad G; Garrigue V; Wolf P; Ellero B; Cassuto E; Albano L; Soulillou JP;
    Transpl Int; 2010 Mar; 23(3):313-24. PubMed ID: 19843296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
    Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.